Track KLRS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Kalaris Therapeutics, Inc.
400 Connell Drive, Berkeley Heights, NJ, United States, 07922
IPO
2020
Employees
20
Industry
Biotechnology
Sector
Healthcare
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20261-1
0
Q4 20250+1
1
2-quarter cumulative
1 sells1 buys
Analyst Ratings
No coverage data
No analyst ratings data available